Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc. today is presenting data from an open-label extension of its Phase IIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD) at the Alzheimer's Association's International Conference on Prevention of Dementia in Washington, D.C. Consistent with the findings of earlier clinical and preclinical studies, AC-1202 was shown to be safe and to significantly improve the memory and cognition of subjects of a particular pharmacogenomic profile.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD at 25 centers across the United States. AC-1202 was administered once daily, and most patients continued to take their other AD drugs such as acetylcholinesterase inhibitors. Following three months of treatment and a two-week washout, eligible subjects were given the opportunity to receive AC- 1202 in a six-month open-label extension study. The main clinical outcome for efficacy was improvement in the AD Assessment Scale-Cognitive (ADAS-Cog) score, which measures memory and other aspects of cognitive performance.

In the double-blind phase of the clinical study the ADAS-Cog scores of the AC-1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01) compared to the placebo group, and statistically significant improvement was seen in just 45 days. ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5-point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease.

As in the double-blind phase of the study, the most profound effect was seen in subjects not expressing the ApoE4 genotype, a genetic risk factor for AD. ApoE4(-) subjects represent the other half of Alzheimer's patients. ApoE4(-) subjects who started taking AC-1202 on the open-label e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/1/2008)...e-FirstCall/ -- GeoVax Labs, Inc.,(OTC Bulletin B...y developing,human vaccines for diseases caused b...infectious agents, announced today that the launch...lace in twelve sites across North and South Americ...th The National Institutes of,Health (NIH), and t...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/25/2008)...ove recovery , , Audio and Web Video Resour...ayo Clinic News Blog. Please see the bottom of thi...Minn., Nov. 25 A Mayo C...n,t think they,re having a stroke -- and as a resu...n worsens. The findings appear in the current issu...
(Date:11/25/2008)... Pharmacyclics, Inc.,(N...as completed a Phase 1,clinical trial with PCI-27...lecule Factor VIIa inhibitor. The trial was conduc...e the safety and pharmacologic effect of,PCI-2748...n a linear dose,response in the International Nor...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 1Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 2Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 1Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 2Surface tension drives segregation within cell mixtures 5244 1Surface tension drives segregation within cell mixtures 5244 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 1Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 3
...ase 1 Colorectal and Prostate Cancer,Trials To Be ...RANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCa...ceutical company,focused on oncology, today announ...the Company,s lead product candidate, in patients,...ed in a poster,session at the 43rd Annual Meeting ...
...07 /PRNewswire-FirstCall/ -- Vical,Incorporated to...study, a DNA vaccine formulated with the company,s...needle-free injection,yielded significantly higher...ne delivered by needle and syringe. In a,separate ...of,unformulated vaccine yielded comparable improve...
Other Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
(Date:12/2/2008)...a leading provider of onsite health services and t...e, the athletic products company, has selected Mar...te health clinics and to provide health services t... Burlington, VT (PRWEB) Decem... of onsite employee health services and technology...
(Date:12/2/2008)...nal Day of Disabled Persons is recognized on Dec. ...g boy born with backwards pointing feet. After fre...ospital docked in Liberia, Benedict,s feet are cor...children his age. High resolution photos and vid...g , Garden Valley, TX (V...
(Date:12/2/2008)...unces that the SouthEast Alaska Regional Health Co...the Rhapsody™ Integration Engine to help the...armacy, laboratory and business programs communica...tivity to statewide systems such as VacTrAK (the S...an MIS and clinical documentation tool used by sub...
(Date:12/2/2008)...orola, Inc. (NYSE: MOT ),announced today that i...enable,three hospitals managed by leading Europea...to deliver voice, data and video services. The inn... broadband infrastructure to support,multimedia s..., eliminating,the need for additional cabling or ...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Mercy Ships Recognizes International Day of Disabled Persons 2Health News:Mercy Ships Recognizes International Day of Disabled Persons 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 2Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 3
...al cardiologist at the Washington Hospital Center ...ergy) to restore blood flow in blocked arteries. /...eople suffering from advanced diabetes as it leads...ns such as amputation. People with diabetes and e...
...s of Kryptiq's Care Manager Diabetes Module at the...ems Society (HIMSS) conference. // This module ...nts who benefited. The one year study showed that ...holesterol and blood pressure levels. Providence M...
...y men contact in Hong Kong has been in a way respo... a latest report. // Government health officials ...vember 2005, had HIV with similar gene sequencing,...st reported. The discovery was made when all the ...
...d be as simple as swallowing a spongy pill with a ...ts of Cambridge University researchers // that can... UK every year. It is the ninth most commonly occu...he windpipe, the pill is pulled out, gently scrapi...
Other Medicine News:Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2Health News:Kryptiq Care Manager Diabetes Module Effective In Managing Diabetes 2
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 5-8; contains 1 bottle each of 20 nm and 40 nm Naked Gold
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 12 OD
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD
Medicine Products: